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Abstract
Background: This study evaluates the dose distribution of reversed planned tangential beam intensity modulated
radiotherapy (IMRT) compared to standard wedged tangential beam three-dimensionally planned conformal
radiotherapy (3D-CRT) of the chest wall in unselected postmastectomy breast cancer patients
Methods: For 20 unselected subsequent postmastectomy breast cancer patients tangential beam IMRT and
tangential beam 3D-CRT plans were generated for the radiotherapy of the chest wall. The prescribed dose was 50
Gy in 25 fractions. Dose-volume histograms were evaluated for the PTV and organs at risk. Parameters of the dose
distribution were compared using the Wilcoxon matched pairs test.
Results: Tangential beam IMRT statistically significantly reduced the ipsilateral mean lung dose by an average of
21% (1129 cGy versus 1437 cGy). In all patients treated on the left side, the heart volume encompassed by the
70% isodose line (V70%; 35 Gy) was reduced by an average of 43% (5.7% versus 10.6%), and the mean heart dose
by an average of 20% (704 cGy versus 877 cGy). The PTV showed a significantly better conformity index with IMRT;
the homogeneity index was not significantly different.
Conclusions: Tangential beam IMRT significantly reduced the dose-volume of the ipsilateral lung and heart in
unselected postmastectomy breast cancer patients.
Background
Breast cancer is the most common cancer in females
worldwide. In the United States and Europe, the most
common treatment is breast conserving surgery followed
by adjuvant radiotherapy [1]. In other parts of the world
including the Middle East, the majority of the patients
present in a more advanced stage of disease at diagnosis,
and mastectomy is the most common treatment fol-
lowed by adjuvant radiotherapy of the chest wall [2].
Large prospective trials [3] and a meta-analysis [4]
have shown that adjuvant radiotherapy of the chest wall
improves local control and survival in node positive
breast cancer patients after mastectomy. The adjuvant
radiotherapy of the chest wall is commonly achieved
with tangential beams, similar to the treatment techni-
que used for the adjuvant whole breast radiation in
early breast cancer. The tangential beams include part
of the anterior thoracic cavity, thereby potentially affect-
ing the organs at risk, in particular the lung and heart.
Randomized, retrospective and population based stu-
dies have shown that the radiotherapy of the chest wall
is associated with a significantly increased risk of devel-
oping ipsilateral second lung cancer [5-12], and in
patients treated on the left side with a significantly
increased risk of cardiac morbidity and mortality
[4,13-24].
There is a good body of literature showing that
inversed planned intensity modulated radiotherapy
(IMRT) potentially leads to a more favourite dose distri-
bution compared to three-dimensional planned confor-
mal radiotherapy (3D-CRT) for the radiotherapy of the
whole breast after breast conserving surgery [25-48].
Data on the effect of IMRT of the chest wall in post-
mastectomy breast cancer patients are scarce in the lit-
erature [49-51]. There are distinct differences between
the target volume of the chest wall and the whole
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breast. The shape of the target volume of the chest wall
is usually shallower compared to the whole breast. In
addition, in stage I-IIa patients the pectoralis muscle,
chest wall muscles, and ribs may be excluded in the tar-
get volume of the whole breast, whereas these structures
are included in the target volume of the chest wall. Due
to these differences in the target volume, results of a
dosimetric study of the radiotherapy of the whole breast
may not be completely applicable to the radiotherapy of
the chest wall.
This study specifically evaluates the dose distribution
of tangential beam IMRT of the chest wall in postmas-




For 20 unselected consecutive postmastectomy breast
cancer patients an opposed tangential beam IMRT plan
and a standard opposed tangential beam 3D-CRT plan
was generated for the radiotherapy of the chest wall.
Thirteen patients had right-sided breast cancer and
seven left-sided. The target volumes were defined and
the dose prescribed according to the International Com-
mission on Radiation Units and Measurement (ICRU)
Reports 50 and 62 recommendations. Accordingly, the
target volume should be surrounded by the 95% isodose
line. The planning target volume (PTV) definition for
the chest wall was done according to the breast cancer
atlas for radiation therapy planning consensus defini-
tions of the Radiation Therapy Oncology Group
(RTOG) http://www.rtog.org/CoreLab/ContouringA-
tlases/BreastCancerAtlas.aspx. The PTV included the
chest wall with the pectoralis muscle, chest wall mus-
cles, and ribs, and excluded the outermost 3 mm from
the superficial skin surface. The heart was defined as all
visible myocardium, from the apex to the right auricle,
atrium, and infundibulum of the ventricle. The pulmon-
ary trunk, root of the ascending aorta, and superior
vena cava were excluded.
This retrospective planning study was approved by the
Institutional Review Board and Ethics committee. For
the statistical analysis, the patient data were anonymized
to guarantee privacy.
Treatment techniques
A non-contrast CT-simulation was performed in the
supine position on a carbon breast board with the ipsi-
lateral arm up and head turned to the contralateral side.
Radio-opaque wires were used to mark the mastectomy
scar and the clinical boundaries. A CT scan was per-
formed using 5 mm slice thickness. The CT scanning
reference point was defined using the CT simulation
software Coherence Dosimetrist (Siemens Medical), and
target volumes (PTV and organs at risk) using the soft-
ware Coherence Oncologist (Siemens Medical). The 3D-
CRT and IMRT plans were generated using the treat-
ment planning system XIO 4.4 (CMS, Inc. of St. Louis,
Mo, USA). A Siemens Oncor Anvantgarde linear accel-
erator with dual photon energy of 6 MV and 15 MV
and multileaf collimator was used for the treatment.
The leaf width was 1 cm at the isocenter. The dose cal-
culation was determined using the “Superposition” algo-
rithm. The prescribed total dose was 50 Gy in 25
fractions. The beam energy of 6 MV was used for all
3D-CRT and IMRT plans because of the better dose
coverage of the chest wall due the lower penetration
power compared to 15 MV.
Tangential beam 3D-CRT
The dose was prescribed to the ICRU reference point
which was usually the isocenter located in the PTV
volume centroid. Two tangential semi-opposed beams
(to avoid divergence), physical wedges (usually 15° or
30°), and a multileaf collimator were used for 3D-CRT.
The beam angles, wedge angles, and beam weighting
(usually minimal) were chosen to optimize coverage of
the PTV, while minimizing exposure to the ipsilateral
lung, heart and contralateral breast. Gantry angles ran-
ged from 42° to 55° for the medial fields and from 224°
to 232° for the lateral fields for patients treated on the
right side, and from 305° to 322° for the medial fields
and from 133° to 147° for the lateral fields for patients
treated on the left side. The fields extended 2 cm ante-
riorly of the chest to provide coverage of the “flash”
region.
IMRT technique
The same beam orientations and angles of the 3D-CRT
plan were used for the tangential beams of the corre-
sponding IMRT plan. The PTV included the same PTV
used for the 3D-CRT plans plus an extension into the
air anteriorly of the chest of 1.5 cm to ensure appropri-
ate opening of the multileaf collimator. The dose was
prescribed to the PTV, and as initial dose volume con-
straints the IMRT prescription table provided by the
XIO treatment planning system was used (Table 1). Tis-
sue inhomogeneities were considered in the treatment
planning optimization process, and the dose calculation
algorithm used was “Superposition”. A step-and-shoot
technique was applied. An optimization with 100 itera-
tions was then applied, and followed by a semiautomatic
segmentation (minimum 3 cm step size). Segments with
less than ≤2 MU were expelled from the plan.
Dose volume histograms of the PTV and organs at
risk of the 3D-CRT and IMRT plans were generated
and dose parameters compared. The Homogeneity index
(HI) was defined as the fraction of the PTV with a dose
between 95% and 105% of the prescribed dose (V95% -
V105%). The Conformity Index (CI) was defined as the
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fraction of the PTV surrounded by the reference dose
(V95%) multiplied by the fraction of the total body
volume covered by the reference PTV dose ((PTV95%
/PTV) × (PTV95% /V95%)).
Statistics
IMRT and 3D-CRT plan parameters derived from the
same patient were tested for statistically significant dif-
ference using the Wilcoxon matched pairs test. All P
values were two-tailed. No correction for multiple test-
ing was used.
Results
Table 2 compares plan parameters of opposed tangential
beam IMRT with conventional 3D-CRT for the adjuvant
radiotherapy of the chest wall in 20 unselected consecu-
tive breast cancer patients after mastectomy. Figure 1
demonstrates typical dose distributions of an IMRT and
3D-CRT plan of the same patient.
Concerning the PTV (chest wall), tangential beam
IMRT significantly improved the conformity index com-
pared to 3D-CRT. The maximum and mean dose was
higher in the IMRT plans, but the differences were
small (about 1%). The Homogeneity Index was not sig-
nificantly different between the IMRT and 3D-CRT
plans.
All patients treated on the left side showed a reduc-
tion of the V70% (percentage of volume encompassed
by the 70% isodose line; corresponding to the volume
receiving ≥35 Gy) of the heart with an average of 43%
(P < 0.01). The mean heart dose was reduced by an
average of 20%. The ipsilateral mean lung dose was sta-
tistically significantly reduced by an average of 21%.
The mean volume and the standard deviation (1SD) of
the PTV (chest wall) was 612.0 cm3 (173.7 cm3), of the
heart 524.2 cm3 (125.5 cm3), and of the ipsilateral lung
1136.7 cm3 (244.4 cm3).
Discussion
A number of studies have demonstrated a dosimetric
benefit of IMRT compared to 3D-CRT for the whole
breast in early breast cancer patients. Data about the
impact of IMRT on the adjuvant radiotherapy of the
chest wall in postmastectomy patients are scarce in the
literature. There are distinct geometric differences
between the target volume of the chest wall and the
Table 1 Dose-volume constraints for IMRT plans
Structure Type Rank Objective Dose (cGy) Volume (%) Weight
PTV Target 1 Maximum 5200 0 100
PTV Target 1 Minimum 4900 100 100
Ipsilateral lung Organ at risk 2 Maximum 2000 20 100
Ipsilateral lung Organ at risk 2 Minimum 1200 30 100
Heart Organ at risk 3 Maximum 4500 0 100
Unspecified tissue Organ at risk 4 Maximum 4500 0 100
IMRT, intensity modulated radiotherapy; PTV, planning target volume.
Table 2 Relevant plan parameters of tangential beam IMRT versus tangential beam 3D-CRT of the adjuvant




Mean 1SD Mean 1SD Difference Difference (%) P value
Ipsilateral chest wall (PTV)
Maximum Dose (cGy) 5530 146 5462 135 68 1 0.04
Mean Dose (cGy) 5083 73 5038 70 44 1 0.04
Homogeneity Index 0.73 0.15 0.77 0.11 -0.05 -6 n. s.
Conformity Index 0.32 0.04 0.25 0.14 0.07 26 0.03
Heart*
Maximum Dose (cGy) 3874 1729 4990 180 -1116 -22 n. s.
Mean Dose (cGy) 704 295 877 272 -173 -20 0.03
V70% 5.71 3.40 10.61 3.68 -4.90 -46 <0.03
Ipsilateral lung
Mean Dose (cGy) 1129 188 1437 204 -308 -21 <0.01
D30% 960 537 1695 875 -734 -43 <0.01
3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; 1SD, standard deviation; V70%, percentage of tissue volume
encompassed by the 70% isodose line (35 Gy); D30%, dose to 30% of the volume (PTV or Organs at risk); *, Patients with left-sided breast cancer only; n.s., not
significant.
Rudat et al. Radiation Oncology 2011, 6:26
http://www.ro-journal.com/content/6/1/26
Page 3 of 7
whole breast, and these differences might have an
impact on the resulting dose distribution. This study
was undertaken to evaluate the dose distribution of tan-
gential beam IMRT of the chest wall compared to tan-
gential beam 3D-CRT in unselected postmastectomy
breast cancer patients.
Our data show that tangential beam IMRT of the
chest wall compared to 3D-CRT significantly reduces
the ipsilateral lung dose-volume (D30% by 43%), and
heart dose-volume in patients treated on the left side
(V70% by 46%). Similar results have been reported for
tangential beam IMRT for the whole breast in early
breast cancer patients. In a recent study, Smith et al.
compared three tangential beam IMRT plans with con-
ventional tangential beam 2 D plans for the adjuvant
radiotherapy of the whole breast in 20 patients with
early breast cancer [52]. All IMRT plans showed a sig-
nificant improvement of the PTV homogeneity index of
15%, heart V30% of 28-33%, and whole lung V20% of 2-
8% compared to the conventional technique.
A significantly better sparing of the high-dose volume
of the heart in selected early breast cancer patients with
unfavourable thoracic geometry has been reported by
the use of multifield IMRT [53,54]. Compared to 3D-
CRT, multifield IMRT reduced the heart volume receiv-
ing ≥30 Gy by 87% [53], or ≥35 Gy by 81% [54]. Model
calculation using a relative seriality model [55] suggested
that the excess cardiac risk was decreased from approxi-
mately 6% to <1% in these patients [53]. On the other
hand, in contrast to our study using tangential beam
IMRT, multifield IMRT significantly increased the mean
heart dose by an average of 24.4% [53], the left lung
D30% by 143% [53], and the volume of the left lung
receiving ≥20 Gy by 47%[54].
It is difficult to precisely estimate the possible clinical
effect of the heart dose-volume reduction by the use of
multifield versus tangential beam IMRT. Clinically recog-
nized presentations of radiation induced heart disease
have been observed in patients who received therapeutic
doses of about ≥35 Gy to partial volumes of the heart
[56]. Recent studies based on atom bomb survivors also
suggest a relationship between cardiac mortality and low
radiation doses in the range of ≤4 Gy [57-60]. The devel-
opment of radiation-related heart disease is a complex
process involving different heart structures with different
radiosensitivities and pathomechanisms, and is still not
well understood [61,62]. Furthermore, pre-existing cardi-
ovascular risk factors as smoking, obesity, and hyperten-
sion as well as the use of cardiotoxic agents such as
anthracyclines, paclitaxel and trastuzumab are likely to
contribute to the development of radiation-related heart
disease. In view of the potential risks it has been recom-
mended that all measures should be attempted to reduce
cardiac radiation exposure [61].
An increased risk of secondary tumors has been
observed in breast cancer patients treated with older
radiation techniques, which combined higher radiation
dose and larger tissue volumes [5,11,12,63,64]. Modern
radiotherapy techniques as 3D-CRT are likely to reduce
the secondary cancer risk by reducing the lung dose-
volume [65]. Smoking has been shown to significantly
increase the risk of second lung cancer in radiotherapy
patients even if modern radiation techniques were used
[66,67].
Multifield IMRT has been discussed to possibly
increase the risk of second cancers [68]. The reason for
this is that compared to 3D-CRT a larger volume of
healthy tissue is being irradiated with lower doses due
to the use of multiple beams and the high number of
monitor units.
Prospective studies with long follow-up times are
needed to fully evaluate the cardiac toxicity and second-
ary lung cancer risk in breast cancer patients treated
with tangential beam or multifield IMRT.
Conclusions
Tangential beam IMRT for the radiotherapy of the chest
wall of postmastectomy breast cancer patients offers the
Figure 1 Dose distribution (V107%, V95%, V90%, V70%) for (a) conformal three-dimensional (3D-CRT) and (b) intensity modulated
radiotherapy (IMRT) plans.
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potential to significantly reduce the dose-volume of the
ipsilateral lung, and in patients with left-sided cancer
the dose-volume of the heart compared to tangential
beam 3D-CRT. These results are similar to those
reported for tangential beam IMRT of the whole breast
in early breast cancer. In selected patients with unfa-
vourable thoracic geometry, multifield IMRT has been
shown to reduce the heart high dose-volume more
effectively, but on the cost of an increased mean heart
dose and ipsilateral lung dose compared to tangential
beam IMRT.
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